No Detail Found!

Drug approval processes: A case study of rivaroxaban

Author(s)
Sally A. Arif Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Cardiology, Chicago
Zainab Bilfaqi Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Illinois, USA
Abstract
Rivaroxaban, a Xa inhibitor, was recently approved (March 2013) in the setting of post-acute coronary syndromes (ACS) by the European Medicine Agency. This is in contrast to not being approved by the Food and Drug Agency in the United States for the same indication in 2012 and 2013. The FDA's decision was based on a lack of follow-up data for the patients enrolled in the study based on the pivotal Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome (ATLAS-ACS 2T-IMI 51) trial. While both agencies have similar roles when functioning as drug regulatory bodies and goal of granting approval of safe and efficacious drugs, the difference in approval outcome in the case of rivaroxaban highlights the differences in drug review process when both agencies are presented with the same Phase 3 data to review.
Publication Details
Page(s) 186-189
DOI DOI not available
Published Journal: Archives of Pharmacy Practice, Volume: 4, Issue: 4, Year: 2013

Request the full text from PASTIC

Keywords
food and drug administration, Drug approval process European medicines agency, rivaroxaban
References
Pharmaceutical Janssen . .Xarelto package insert; 2013 Available from. [Last accessed on 2013 Oct, 31 : .
Administration Drug . .. United States. c2013 Xarelto Medication Guide, : .
. .?curl=pages/ m e d i c i n e s / h u m a n / m e d i c i n e s / 0 0 0 9 4 4 / h u m a n _ med_001155.jsp [Last accessed on 2013 June]. European Union. C2013 Xarelto Public Assessment Report, : .
'Gara O,Kushner PT,Ascheim FG,Casey DD,Chung DE,de Lemos MK,JA MK .2013 .American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for management of ST‑elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 127 : 362-425.
Administration Drug . .Development and Drug Approval Process. htm [Last accessed on 2013 Oct, 31 : .
Medicines European . .Over view. WC0b01ac0580028a43. [Last accessed on 2013 Oct, 31 : .
Downing NS,Aminawung JA,Shah ND,Braunstein JD,Krumholz HW,Ross JS .2012 .Regulatory review of novel therapeutics‑ comparison of three regulatory agencies. N Engl J Med, 367 : 1165-7.
Gidron M,Hollis C,Jones E. European Medicines Agency Do Not Mirror FDA. FDL C .2008 .. , 805 : 1-12.
Administration Drug . .. htm [Last accessed on 2013 Oct, 31 : .
Mega JL,Braunwald E,Wiviott SD,Bassand JP,Bhatt DL,Bode C .2012 .Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med, 366 : 9-19.
Administration Drug . .FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) for Xarelto® (Rivaroxaban) oral tablets c 2012 Available from. page=192 [Last accessed on 2013 Oct, 31 : .
.2013 .Drug approval processes: A case study of rivaroxaban. Arch Pharma Pract, 4 : 186-9.
0

Citations

0

Downloads

11

Views